INS and obesity disorder: Interactions with these receptors makes THCV a good candidate for efficacy in the treatment of obesity and diabetes (Pertwee 2008; Tudge et al. 2014; Jadoon et al. 2016; Abioye et al. 2020; Wargent et al. 2020), treatment of insulin insensitivity due to obesity (Wargent et al. 2013), treatment of skin inflammation (Tortolani et al. 2023), treatment of dyskinesia in Parkinson’s disease (García et al. 2011; Espadas et al. 2020), and treatment of seizures (Hill et al. 2010).